- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07541352
휴고 RAS 대장암 협업 그룹 (HRCC)
휴고 RAS 대장암 협력 연구(HRCC): 최소 침습 수술 발전을 위한 국제 연구
The Hugo RAS Colorectal Collaborative (HRCC) is an international, multicenter dataset of patients undergoing colorectal surgery using the Hugo RAS system. The registry aims to analyze short and long-term outcomes to provide real-world evidence on the safety and effectiveness of the system.
연구 개요
상태
상세 설명
This prospective observational study will gather data via standardized electronic Case Report Forms (eCRFs) across multiple international high-volume colorectal surgery centers. The study intends to foster the standardization of surgical techniques, evaluate the learning curve of surgeons, and identify surgical best practices for the Hugo RAS modular system. The total expected duration for the initial phase is approximately 3 years, followed by extended long-term follow-up.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Matteo Rottoli, MD, PhD
- 전화번호: +390516364823
- 이메일: matteo.rottoli@unibo.it
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adult patients (≥18 years) undergoing any type of elective or emergent colorectal surgery using the Hugo RAS system. The population will be drawn from participating high-volume colorectal surgery centers across multiple countries. All eligible patients at these centers will be enrolled to minimize selection bias.
설명
Inclusion Criteria:
- Adult patients (age ≥ 18 years)
- Scheduled to undergo any type of colorectal surgery (elective or emergent) where the Hugo RAS system is planned to be used
- Willing and able to provide written informed consent
Exclusion Criteria:
-Patients unable to provide informed consent
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: OTHER
코호트 및 개입
그룹/코호트 |
|---|
|
Patients undergoing Hugo RAS colorectal surgery
Adult patients (≥18 years) scheduled to undergo any type of elective or emergent colorectal surgery utilizing the Hugo™ RAS (Robotic-Assisted Surgery) System at participating high-volume colorectal surgery centers. The intervention of interest is the use of the Hugo RAS System, a medical device manufactured by Medtronic, which consists of a surgeon console, robotic arms with instrument manipulators, and a vision cart. The system is intended for performing minimally invasive colorectal surgical procedures. Because this is an observational study, patients will receive treatment according to the standard clinical practice of the participating centers. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Complications
기간: Intraoperatively
|
Number of participants experiencing intraoperative complications, which will include the recording of robotic arm conflicts, system alarms (including red alarms), and any technical difficulties encountered. |
Intraoperatively
|
|
Rate of Postoperative Complications
기간: Postoperatively (30-day and 90-day)
|
Number and severity of postoperative complications assessed using the Clavien-Dindo classification system |
Postoperatively (30-day and 90-day)
|
|
Operative Time
기간: Intraoperatively
|
Total duration in minutes of the surgical procedure measured to evaluate the efficacy of the Hugo RAS system. |
Intraoperatively
|
|
Blood loss
기간: Intraoperatively.
|
Measurement of blood loss during the surgical procedure. (ml) |
Intraoperatively.
|
|
Conversion Rate
기간: Intraoperatively.
|
Measurement of conversion rates to open or traditional laparoscopic surgery (%) |
Intraoperatively.
|
|
Length of Hospital Stay
기간: At discharge, assessed up to 90 days post-surgery
|
Total length (days) of patient hospital stay post-surgery. |
At discharge, assessed up to 90 days post-surgery
|
|
Hospital Readmission Rate
기간: Up to 90 days post-surgery
|
Rate of hospital readmissions following discharge. |
Up to 90 days post-surgery
|
|
Pathological Outcomes: Margin Status and Lymph Node Yield
기간: Up to 30 days post-surgery
|
Assessment of pathological outcomes, specifically evaluating margin status and lymph node yield. |
Up to 30 days post-surgery
|
|
Disease Recurrence Rate
기간: Up to 5 years post-surgery
|
Monitoring of disease recurrence rates post-surgery. |
Up to 5 years post-surgery
|
|
Overall and Disease-Free Survival
기간: Up to 5 years post-surgery
|
Collection of survival data, specifically overall survival and disease-free survival rates. |
Up to 5 years post-surgery
|
|
Long-term Functional Outcomes
기간: Long-term follow-up (e.g., 1 year, 3 years post-surgery).
|
Assessment of long-term functional outcomes, such as bowel function. |
Long-term follow-up (e.g., 1 year, 3 years post-surgery).
|
|
Bowel Function Assessed by the LARS Score
기간: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
Bowel function will be evaluated using the unabbreviated Low Anterior Resection Syndrome (LARS) score questionnaire. The total score ranges from 0 to 42. A score of 0 to 20 indicates no LARS, 21 to 29 indicates minor LARS, and 30 to 42 indicates major LARS. Higher scores indicate worse bowel function and a worse outcome. |
Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
|
Fecal Incontinence Assessed by the Wexner Scale
기간: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
Fecal incontinence will be evaluated using the Cleveland Clinic (Wexner) Fecal Incontinence Score. The scale assesses the frequency of different types of incontinence and lifestyle alterations. The total score ranges from 0 to 20, where 0 represents perfect continence and 20 represents complete incontinence. Higher scores indicate more severe incontinence and a worse outcome. |
Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
|
Quality of Life Assessed by the EORTC QLQ-C30
기간: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). All scale and single-item measures are linearly transformed to a score ranging from 0 to 100. For the global health status and functional scales, a higher score represents a better level of functioning and a better quality of life. For the symptom scales and items, a higher score represents a higher level of symptomatology and a worse quality of life. |
Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
|
Health-Related Quality of Life Assessed by the EQ-5D-3L
기간: Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
Health status will be evaluated using the EuroQol-5 Dimension-3 Level (EQ-5D-3L) questionnaire. This tool consists of a descriptive system and a Visual Analogue Scale (VAS). The descriptive system assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, which are converted into a single health utility index score (typically ranging from less than 0 to 1.0, where 1.0 represents full health). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale ranging from 0 to 100. For both the index score and the VAS, higher scores indicate a better health status and a better outcome. |
Baseline, 6 months, 1 year, 2 years, and 3 years post-surgery
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Romero-Marcos JM, Sampson-Davila JG, Cuenca-Gomez C, Altet-Torne J, Gonzalez-Abos S, Ojeda-Jimenez I, Galaviz-Sosa ML, Delgado-Rivilla S. Colorectal procedures with the novel Hugo RAS system: training process and case series report from a non-robotic surgical team. Surg Endosc. 2024 Apr;38(4):2160-2168. doi: 10.1007/s00464-024-10760-8. Epub 2024 Mar 6.
- Rottoli M, Violante T, Calini G, Cardelli S, Novelli M, Poggioli G. A multi-docking strategy for robotic LAR and deep pelvic surgery with the Hugo RAS system: experience from a tertiary referral center. Int J Colorectal Dis. 2024 Oct 1;39(1):154. doi: 10.1007/s00384-024-04728-2.
- Cheng CL, Rezac C. The role of robotics in colorectal surgery. BMJ. 2018 Feb 12;360:j5304. doi: 10.1136/bmj.j5304.
- Irani JL, Hedrick TL, Miller TE, Lee L, Steinhagen E, Shogan BD, Goldberg JE, Feingold DL, Lightner AL, Paquette IM. Clinical practice guidelines for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons and the Society of American Gastrointestinal and Endoscopic Surgeons. Surg Endosc. 2023 Jan;37(1):5-30. doi: 10.1007/s00464-022-09758-x. Epub 2022 Dec 14.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- HRCC
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Requests for access to anonymized individual patient-level data by external researchers will be considered on a case-by-case basis by the HRCC steering committee. A formal data sharing agreement outlining the terms of use, data security, and publication policies will be required. The primary aim is to protect patient confidentiality and ensure that data is used responsibly for advancing scientific knowledge in line with the registry's objectives.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .